Omeprazole
-
Subject Areas on Research
- A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution.
- Advances in drug therapy for peptic ulcer disease.
- Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial.
- Attenuation of acid induced oesophagitis in VR-1 deficient mice.
- Bariatric Embolization: Pilot Study on the Impact of Gastroprotective Agents and Arterial Distribution on Ulceration Risk and Efficacy in a Porcine Model.
- Clinical outcomes in patients with the concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention: an analysis from the Guthrie Health Off-Label Stent (GHOST) investigators.
- Clopidogrel and PPI interaction: clinically relevant or not?
- Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease.
- Endoscopy, nonsteroidal anti-inflammatory drug, and omeprazole regimen in colorectal cancer prevention.
- Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.
- Gastropathy induced by nonsteroidal anti-inflammatory drugs: prescribing patterns among geriatric practitioners.
- Hydroxychloroquine-induced hyperpigmentation: the staining pattern.
- Intravenous proton pump inhibitors in the critical care setting.
- Lack of in vitro activity of omeprazole against Campylobacter pylori.
- Omeprazole: a possible new candidate influencing the antiplatelet effect of clopidogrel.
- Omeprozole therapy in pediatric patients after liver and intestinal transplantation.
- Oral SIV, SHIV, and HIV type 1 infection.
- PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection.
- PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) versus enteric-coated aspirin 325 mg alone in subjects at risk for aspirin-associated gastric ulcers: results of two 6-month, phase 3 studies.
- Pharmacodynamic evaluation of clopidogrel plus PA32540: the Spaced PA32540 With Clopidogrel Interaction Gauging (SPACING) study.
- Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel.